5 days ago
SRRK
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 8%
#416 out of 5515 analysts
Average Return
+22.05%
Win Rate
56%53 out of 95
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +520.24% | $8.50 | $52.72 | 2025-10-15 - 2026-03-31 | Strong Buy |
Mbx Biosciences IncMBX | +350.97% | $13.95 | $62.91 | 2025-10-15 - 2026-09-18 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-13 - 2025-08-12 | Strong Buy |
Terns Pharmaceuticals IncTERN | +202.47% | $17.43 | $52.72 | 2025-11-04 - 2026-03-31 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-28 - 2024-06-27 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
a month ago
PTGX
a month ago
MBX
a month ago
CYTK
2 months ago
PTGX
3 months ago
SEPN
3 months ago
KYMR
4 months ago
MDGL
4 months ago
MBX
4 months ago
VTRS
5 months ago
PTGX
6 months ago
SEPN
7 months ago
SRRK
8 months ago
CYTK
8 months ago
PTGX
9 months ago
KYMR
10 months ago
KYMR
10 months ago
MDGL
2 years ago
LLY
2 years ago
PFE
2 years ago
EWTX
2 years ago
SRRK
2 years ago
LLY
2 years ago
LLY
2 years ago
LLY
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Scholar Rock Holding CorpSRRK | 7 | Strong Buy | $76.00 | +62.92% | Reiterates | 5 days ago |
Protagonist Therapeutics IncPTGX | 7 | Strong Buy | $170.00 | +18.88% | Maintains | a month ago |
Mbx Biosciences IncMBX | 3 | Strong Buy | $88.00 | +39.88% | Maintains | a month ago |
Cytokinetics IncCYTK | 6 | Strong Buy | $112.00 | +62.84% | Maintains | a month ago |
Absci CorpABSI | 2 | Strong Buy | $17.00 | +76.17% | Maintains | 3 months ago |
Septerna IncSEPN | 3 | Strong Buy | $43.00 | +11.14% | Maintains | 3 months ago |
Kymera Therapeutics IncKYMR | 7 | Strong Buy | $136.00 | +15.50% | Maintains | 3 months ago |
Incyte CorpINCY | 13 | Hold | $105.00 | -16.21% | Maintains | 3 months ago |
Madrigal Pharmaceuticals IncMDGL | 3 | Strong Buy | $709.00 | +33.39% | Maintains | 4 months ago |
Viatris IncVTRS | 2 | Strong Buy | $20.00 | +17.99% | Maintains | 4 months ago |
Biogen IncBIIB | 7 | Hold | $189.00 | -12.30% | Maintains | 5 months ago |
Terns Pharmaceuticals IncTERN | 5 | Hold | $53.00 | +0.09% | Downgrades | 6 months ago |
Inventiva SaIVA | 1 | Strong Buy | $13.00 | +243.92% | Initiates Coverage On | 6 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | N/A | Maintains | a year ago |
Arvinas IncARVN | 1 | Hold | $11.00 | N/A | Downgrades | a year ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | N/A | Maintains | 2 years ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | 2 years ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | 2 years ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | 2 years ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.